Cancer rates among people with HIV, particularly AIDS-defining cancers, are projected to decrease by 2030.
AIDS-linked tumors are predicted to decline by 2030.
HIV is associated with reduced cancer-specific survival among women with invasive cervical cancer.
Recent results from a multicenter, phase 2 trial suggest that patients with HIV and aggressive lymphoma should receive autologous stem cell transplant as standard of care. Risk of serious complications after transplant in these patients is equal to that of patients without HIV.
Patients living with HIV are at high risk for lymphoma,according to recent study data, and recent autologous hematopoietic stem-cell transplantation may be preferable for these patients.
Treatment gap exists, but the reasons for the care disparity aren't entirely clear.
Each of these diagnoses has many implications for both nurses and patients. When combined, nurses need to anticipate that these patients may have greater psychosocial challenges.
Longer survival can raise the risk of anal, colorectal, and liver cancers, researchers find.
HIV has been linked to increased risk for colorectal, lung, skin, and breast cancers, independent of treatment.
Proportion undergoing testing varies by demographic and health-related factors, and by state, a study found.
Only 41% of cancer survivors in the U.S. under 65 reported ever having a human immunodeficiency virus (HIV) test.
Adding steroids for the treatment of tuberculosis pericarditis in patients co-infected with HIV may increase the risk of cancer.
HIV-infected people with early stage cancer are two to four times more likely to go untreated for their cancer compared to uninfected patients with cancer, according to a new, large retrospective study.
HIV-infected individuals with cancer are less likely to receive treatment, according to a study published online in the Journal of Clinical Oncology.
Researchers have discovered a promising new way to treat a rare and aggressive blood cancer that is most commonly found in people infected with HIV.
HIV-positive patients have a higher incidence of nonmelanoma skin cancers. Specifically, basal cell and squamous cell carcinomas occur more than twice as often among HIV-positive persons.
In 2010, 32 percent had received three doses of vaccine; incidence of some HPV-linked cancers up.
High incidence compared to general population, especially for men who have sex with men.
Based on the current literature associating human papillomavirus (HPV) with head and neck cancer, what public health initiatives need to be implemented?
Targeted prophylaxis strategy is most cost-effective in highest risk men who have sex with men.
Phase 2 study shows overall response rate of 31 percent in patients with poor-prognosis HIV-KS.
Drugs to keep HIV-infected women from transmitting virus to fetus may trigger cleft defects.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Clinical Trials May Benefit Oncology Patients
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Cancer Risk Not Increased by Childhood Exposure to Diagnostic Radiation
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Breast Cancer Diagnosis and Nurse Navigation Survey
- Radiotherapy is Essential in Treating Brain Tumors But Associated With Significant Adverse Events
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Lenvatinib Improves OS, PFS in Radioiodine-Refractory Differentiated Thyroid Cancer in All Older Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Use of Aspirin, NSAIDs Correlates with Improved Overall Survival in Colorectal Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|